Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Doctoral: Vanier Canada Graduate Scholarships

McGill University

$150,000.00

The Role of Genetics in Chronic Pain

EF 2011-12

Résumé
Chronic pain ranks as one of the most debilitating and common health conditions, more prevalent than cancer, heart disease and diabetes combined. Associated with increased mortality rates (including suicide) and decreased lifespans, chronic pain exacts an enormous economic toll on society. Chronic pain displays immense individual variability, whereby some people recover fully from injuries and infections, while others suffer persistent pain for years. Since much of this variability is known to be genetic, the identification of those genes affecting chronic pain severity is imperative to promote early intervention and drug development. To identify genes related to chronic pain, we used an advanced genetic technique called expression genomics in mice with experimental nerve injury and isolated the Chrna6 gene. Specifically, we found that in strains of mice that experience greater symptoms of nerve (neuropathic) pain, the Chrna6 gene is less active, producing less of its protein product, the alpha6 subunit of the so-called nicotinic receptor. This finding suggests that drugs acting on this receptor might be effective analgesics against chronic pain. To further evaluate this hypothesis, we intend to test transgenic mutant mice with non-functional or abnormally high-functioning Chrna6 genes. We predict that the loss-of-function mice will exhibit higher levels of pain and the gain-of-function mice will experience lower levels. By subjecting these mice to a variety of chronic and acute pain conditions, followed by a series of electrophysiological, behavioural and pharmacological experiments, we intend to elucidate the Chrna6 mechanism of action. By specifically targeting those genes responsible for pain variability, we hope to gain a better understanding of gene involvement in pain perception, ultimately leading to novel therapeutic approaches and individualized treatments that target the symptoms of chronic pain.
Programme
Doctoral: Vanier Canada Graduate Scholarships
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
247708
Name
Wieskopf Jeffrey S
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Neurosciences, Mental Health and Addiction
Theme2
Biomedical
Prcname2
Vanier Canada Graduate Scholarships CIHR
Projecttitle
The Role of Genetics in Chronic Pain
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$150,000
Cihrequipment2
$0
Programname2
Doctoral: Vanier Canada Graduate Scholarships
Keyworddelim
Chronic Pain; Genomic Analysis; Neuropathic Pain; Nicotinic Acetylcholine Receptors
Abstract
Chronic pain ranks as one of the most debilitating and common health conditions, more prevalent than cancer, heart disease and diabetes combined. Associated with increased mortality rates (including suicide) and decreased lifespans, chronic pain exacts an enormous economic toll on society. Chronic pain displays immense individual variability, whereby some people recover fully from injuries and infections, while others suffer persistent pain for years. Since much of this variability is known to be genetic, the identification of those genes affecting chronic pain severity is imperative to promote early intervention and drug development. To identify genes related to chronic pain, we used an advanced genetic technique called expression genomics in mice with experimental nerve injury and isolated the Chrna6 gene. Specifically, we found that in strains of mice that experience greater symptoms of nerve (neuropathic) pain, the Chrna6 gene is less active, producing less of its protein product, the alpha6 subunit of the so-called nicotinic receptor. This finding suggests that drugs acting on this receptor might be effective analgesics against chronic pain. To further evaluate this hypothesis, we intend to test transgenic mutant mice with non-functional or abnormally high-functioning Chrna6 genes. We predict that the loss-of-function mice will exhibit higher levels of pain and the gain-of-function mice will experience lower levels. By subjecting these mice to a variety of chronic and acute pain conditions, followed by a series of electrophysiological, behavioural and pharmacological experiments, we intend to elucidate the Chrna6 mechanism of action. By specifically targeting those genes responsible for pain variability, we hope to gain a better understanding of gene involvement in pain perception, ultimately leading to novel therapeutic approaches and individualized treatments that target the symptoms of chronic pain.
Competitiondate
201111
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Wieskopf, Jeffrey S
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $150,000~ $0~